Hepatic Encephalopathy Clinical Trial
Official title:
Frontal Electroencephalogram Variables Are Associated With Outcome and Stage of Hepatic Encephalopathy in Acute Liver Failure
Neuromonitoring of critically ill patients in the intensive care unit (ICU) is challenging.
Clinical scoring systems produce insufficient information with deeply sedated patients, and
disturbances of normal hemostasis limit the use of invasive intra-cranial pressure
measurements. EEG based monitoring algorithms have been introduced into the operation
theater and general anaesthesia, but these algorithms cannot be used in the intensive care
setting without modifications. EEG is also susceptible to electrical disturbances, such as
those created by patient movement.
The study is conducted in Finland, in the intensive care unit of the Surgical Hospital of
Helsinki. The total number of patients in this study is 20, and it is a part of a larger
neuromonitoring study with a total of 110 patients. The patients are divided into four
subgroups, as follows: 1. patients admitted to ICU with acute liver failure, 2. patients
admitted to the postoperative cardio-thoracic ICU after cardiac surgery with perioperative
total heart arrest, 3. patients admitted to the ICU because of status epilepticus and
finally 4. patients in critical condition, admitted to the ICU after any surgery. This study
concentrates on the first group of patients with acute liver failure.
Clinical care of patients is not altered. When arriving into the ICU EEG-monitoring will
added to routine monitoring. To evaluate the neurological status the following tests are
performed: clinical test, blood tests and transcranial doppler ultrasound. The Entropy of
EEG is measured along with the raw EEG signal.
The recruiting of study patients was begun in December 2005 and the final study patients
were recruited in December 2011. GE Healthcare Finland supplies the entropy monitoring
devices and pays the salary of the research nurses who collect the study data. Clinical
investigators will not receive funding from any commercial company. All patients (or their
next of kin) included have given their written informed consent for inclusion in the study.
The aim of this study is to find new factors and new non-invasive techniques, which
correlate with the neurological state and outcome of patients suffering critical illness.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01559519 -
Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy
|
Phase 4 | |
| Terminated |
NCT01846806 -
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
|
N/A | |
| Recruiting |
NCT01178372 -
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis
|
Phase 4 | |
| Completed |
NCT00914056 -
A Study of Controlled Lactulose Withdrawal
|
N/A | |
| Completed |
NCT00740142 -
Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy
|
Phase 4 | |
| Completed |
NCT00558038 -
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
|
Phase 2 | |
| Completed |
NCT00986895 -
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
|
Phase 1 | |
| Completed |
NCT00287235 -
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
|
N/A | |
| Recruiting |
NCT05539027 -
Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy
|
Phase 4 | |
| Recruiting |
NCT04096014 -
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
|
N/A | |
| Completed |
NCT05526404 -
Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration
|
N/A | |
| Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
| Enrolling by invitation |
NCT06367127 -
Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
|
||
| Active, not recruiting |
NCT05425316 -
Speech in Hepatic Encephalopathy (HE)
|
||
| Recruiting |
NCT04415294 -
Flicker App for Minimal Hepatic Encephalopathy
|
||
| Not yet recruiting |
NCT06072521 -
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
|
Phase 2 | |
| Completed |
NCT02636647 -
Fecal Transplant in Recurrent Hepatic Encephalopathy
|
Phase 1 | |
| Withdrawn |
NCT02086825 -
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
|
Phase 3 | |
| Completed |
NCT01446523 -
S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
|
N/A | |
| Completed |
NCT01218568 -
Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial
|
N/A |